Speedel raises $56M for drug development work

Switzerland's Speedel has raised $56 million through a convertible loan program. The company plans to put the money to use for its drug development work, including a Phase III trial of SPP301 for diabetic kidney disease it is doing on its own. Speedel -- a 2005 Fierce 15 company -- dropped an earlier effort to go public, citing poor market conditions and an unwillingness to take a deep discount on its stock.

- read this press release for more

PLUS: Aureon Laboratories of Yonkers, New York, has garnered $20 million in its second round of venture capital. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.